Lilly's Omvoh scores second IBD win with FDA nod in Crohn's

Eli Lilly has secured FDA approval for Omvoh (mirikizumab-mrkz) in Crohn's disease, marking the IL-23p19 inhibitor's second inflammatory bowel disease (IBD) indication in just over a year following its initial green light in ulcerative colitis.